This is unpublished


he, him, his
Physician & Research Faculty
Associate Professor, Clinical Research Division, Fred Hutchinson Cancer Research Center
Associate Professor, Division of Medical Oncology, University of Washington
Director, Cord Blood Transplantation Program, Fred Hutch
Associate Scientific Director, Cellular Therapy Laboratory, SCCA
Sites of Practice
UW Medical Center - Montlake
Seattle Cancer Care Alliance

Photo: Fred Hutch

Education, Training, Board Certifications 

  • M.D., University La Sapienza, Italy
  • Ph.D., University La Sapienza, Italy
  • Fellowship in Hematology, UW
  • Italian Board of Hematology 


Clinical Expertise

  • Cord blood transplantation
  • Haploidentical Transplantation 




Research and/or clinical interests 

Dr. Filippo Milano is a physician-scientist whose research is focused on the use of umbilical cord blood as a source of stem cells for transplantation to treat blood cancers. He concentrates on clinical practice improvements with a goal of increasing the number of patients eligible for transplantation and to improve clinical outcomes for those who receive cord blood transplants. He has carried out pivotal analyses of blood cancer patients who have received transplants, comparing outcomes of cord blood recipients with those who had blood stem cell transplants from unrelated donors. More recently, Dr. Milano’s research goal has been focused on increasing the use of alternative donor sources, such as cord blood and haploidentical donors, for patients belonging to ethnic and racial minorities who do not have an HLA-identical sibling or unrelated donor. 

Dr. Milano’s current projects include: 

  • Use of Non HLA-matched off-the-shelf ex-vivo expanded cord blood progenitors for patients with HIV undergoing cord blood transplantation.
  • Impact of cord blood expansion with UM-171 molecule in patients with high-risk hematological malignancies.
  • Evaluation of the use of Treosulfan as part of the conditioning regimen in patients undergoing haploidentical transplantation.
  • Use of chemotherapy to improve outcomes in patients with minimal residual disease undergoing allogeneic transplantation.